B cell depletion therapies in autoimmune disease: advances and mechanistic insights.

Nat Rev Drug Discov · 2021 · PMC7737718 · PMID 33324003

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a phase I clinical trial, an anti-CD19 antibody (inebilizumab) showed a trend towards fewer gadolinium-enhancing lesions as well as a reduction in the number of new or newly enlarged T2-weighted lesions 177 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.